İdris KIRHAN, Ferzan AYDIN, Çiğdem CİNDOĞLU, Necati YENİCE, Ahmet UYANİKOGLU

Serum prolidase, urotensin-2 and nesfatin levels in patients with compensated or uncompensated cirrhosis

Aim: To assess the feasibility of serum prolidase, urotensin-2, and nesfatin measurements as diagnostic and follow-up markers ofcompensated or uncompensated cirrhosis.Material and Methods: The study included 97 cirrhosis patients and 51 healthy individuals who were admitted to the InternalMedicine and Gastroenterology Clinics of Harran University Research and Application Hospital between May 2014 and June 2015.Patients with esophageal variceal bleeding, ascites, hepatic encephalopathy were considered as having decompensated cirrhosis.Blood samples obtained from patient and control groups were stored at -85 C. ELISA methodology was used for measurements.Results: A total of 97 cirrhotic patients (43 with compensated and 54 with decompensated cirrhosis) with a median age of53.98±15.67 years (range: 19-89) were included in the study. Serum prolidase, urotensin-2, and nesfatin in patients with cirrhosiscompared to 51 healthy controls. Serum prolidase levels were significantly lower in the overall group of patients with cirrhosisas well as in the decompensated cirrhotic patients as compared to controls (p

PDF

___

1. Bruce A. Runyon. Ascites and Spontaneous Bacterial Peritonitis. In: Mark Feldman, Lawrence S Friedman, Lawrence J Brandt, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2. 9th edition. Philadelphia: Saunders Elsevier, 2006. p. 1259-1279.
2. P. Aiden McCormick. Hepatic cirrhosis. In: Sherlock S, Dooley J, eds. Disease of the liver disease and biliary system. 2th edition. London: Blackwell scientific pub; 2002. p. 365-77.
3. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
4. Baik SK, Fouad TR, Lee SS, Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007;27:2-15
5. Çelik H, Aksoy N, Aslan M, et al. Siroz hastalarında kollajen metabolizmasının bozulması. Turk J Biochem 2005;29:1-172.
6. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its function in disease. Cardiovasc Drugs Ther 2005;19:65-75.
7. Gonzalez R, Shepperd E, Thiruppugazh V, et al. Nesfatin-1 regulates the hypothalamo- pituitary-ovarian axis of fish. Biol Reprod 2012,11;87:84-5.
8. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010;151:3169-80.
9. Başar O, Akbal E, Köklü S, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012;72:479-83.
10. Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic ınflammation and cirrhosis. J Hepatol 2014;61:396-407.
11. Boright A, Scrıver CR, Lancaster GA, et al. Prolidase deficiency: biochemical classification of alleles. Am J Hum Genet 1989;44:731-40.
12. Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin-II induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-4.
13. William K, Andrew K, Arintaya P. Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. Am J Physiol Gastrointest Liver Physiol 2009;297:762-7.
14. Dıangang Lıu, Jıng Chen, Jın Wang, et al. Increased expression of urotensin II AND GPR14 in patients with cirrhosis and portal hypertension. Int J Molr Med 2010;25:845-51.
15. Pawer R, Kemp W, Roberts S, et al. Urotensin 2 levels are an important marker for the severity of portal hypertension in children. J Pediatr Gastroenterol Nutr 2011;53:88-92.
16. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709-12.
17. Zegers D, Beckers S, Mertens IL, et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Molecul Genetics Metabol 2011;103:282-6.
18. Başar O, Akbal E, Köklü S, et al. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012;72:479-83.